AZD1152 in Patients With Advanced Solid Malignancies

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Timeline

Start

2006-05-23

Primary completion

2008-06-06

Completion

2017-03-01

Drugs

Indications